Have a feature idea you'd love to see implemented?
Let us know!
BHVN Biohaven Ltd
Price (delayed)
$45.59
Market cap
$4.61B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$9.41
Enterprise value
$4.55B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
Highlights
The company's debt fell by 11% YoY and by 3.4% QoQ
The equity has declined by 18% since the previous quarter but it has increased by 9% year-on-year
Biohaven's net income has plunged by 73% YoY and by 8% from the previous quarter
BHVN's quick ratio is down by 36% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of BHVN
Market
Valuations
Earnings
Shares outstanding
101.12M
Market cap
$4.61B
Enterprise value
$4.55B
Price to earnings (P/E)
N/A
Price to book (P/B)
13.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$804.86M
EBITDA
-$797.57M
Free cash flow
-$531.06M
Per share
Balance sheet
Liquidity
EPS
-$9.41
Free cash flow per share
-$5.63
Book value per share
$3.34
Revenue per share
$0
TBVPS
$5.2
Total assets
$510.52M
Total liabilities
$194.52M
Debt
$25.31M
Equity
$316.01M
Working capital
$288.21M
Debt to equity
0.08
Current ratio
2.89
Quick ratio
2.49
Net debt/EBITDA
0.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-158.9%
Return on equity
-225.1%
Return on invested capital
-380.2%
Return on capital employed
-224.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BHVN stock price
How has the Biohaven stock price performed over time
Intraday
0.89%
1 week
2.7%
1 month
-13.41%
1 year
50.61%
YTD
6.52%
QTD
-8.77%
Financial performance
How have Biohaven's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$848.89M
Net income
-$804.34M
Gross margin
N/A
Net margin
N/A
Biohaven's net income has plunged by 73% YoY and by 8% from the previous quarter
The company's operating income has shrunk by 71% YoY and by 9% QoQ
Growth
What is Biohaven's growth rate over time
Valuation
What is Biohaven stock price valuation
P/E
N/A
P/B
13.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 30% year-on-year and by 2.2% since the previous quarter
The stock's P/B is 20% above its last 4 quarters average of 11.4
The equity has declined by 18% since the previous quarter but it has increased by 9% year-on-year
Efficiency
How efficient is Biohaven business performance
Biohaven's return on invested capital has shrunk by 124% YoY
The ROE has plunged by 104% YoY and by 6% from the previous quarter
The ROA has plunged by 86% YoY
Dividends
What is BHVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BHVN.
Financial health
How did Biohaven financials performed over time
The company's total assets is 162% higher than its total liabilities
The total liabilities has soared by 110% YoY but it has contracted by 2.2% from the previous quarter
The current ratio has declined by 42% year-on-year and by 12% since the previous quarter
The company's debt is 92% lower than its equity
BHVN's debt to equity is down by 20% year-on-year but it is up by 14% since the previous quarter
The equity has declined by 18% since the previous quarter but it has increased by 9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.